Kornimate/medical-research-clean huggingface dataset:
traumeel for post-tonsillectomy pain

Conditions: Post-Tonsillectomy

Summary: tonsillectomy is one the most common procedures in ear, nose and throat (ent) medicine. following surgery patients suffer from severe pain and difficulty on swallowing, while analgesic treatment has limited efficacy and potential adverse effects such as increased bleeding with nsaids. traumeel s is a homeopathic complex remedy used primarily in europe for the treatment of pain and inflammation. it contains a number of plants and minerals at high dilutions (between 1x10-2 to 1x10-8), and has been shown to exhibit anti-inflammatory properties such as cytokine inhibition in human t cells, monocytes and gut epithelial cells. clinical studies have found traumeel s reduces post-chemotherapy stomatitis, as well as post-surgical inflammation and pain following orthopedic procedures. the purpose of this study is to examine the effect of traumeel s on post-tonsillectomy pain in adult patients. the study group will consist of 20 patients age 18 years of age and older following elective tonsillectomy. these patients will be randomly assigned to receive treatment with either true traumeel s remedies or placebo. one ampule of traumeel s (or placebo) will be sprayed over the resected area immediately following surgery. two traumeel s (or placebo) tablets will be taken subsequently 4 times daily (total: 8 tablets per day)until no analgesics are required for 2 consecutive days, or until day 14 (whichever comes first). patients will be allowed to take dipyrone (optalgin) 500mg tablets on an as-needed basis, for up to 14 days postoperatively. at the end of this period, a thorough ent examination will be done. the primary parameter to be evaluated in the study will be postoperative pain, as registered on a numerical pain rating scale (nrs), to be filled prior to surgery. in the post-anesthesia care unit (paca) the nrs will be filled out again, this time for pain at rest and then again for pain upon swallowing - at 1, 2, 3,4 and 24 hours postoperatively. secondary parameters to be evaluated are: analgesic use (dipyrone); post-operative bleeding (quantified on a scale of 1-4); nocturnal awakenings; time to resumption of eating and return to normal activity; cytokine levels (crp, il-6) at 36 hours postoperative; and side effects of the treatment.


Eligibility criteria:
inclusion criteria: * age 18 years and older * recurrent tonsillitis or obstructive tonsillar hypertrophy requiring tonsillectomy. exclusion criteria: * elective or emergency tonsillectomy for a reason other than those listed above. * history of peritonsillar abscess, or need for additional ent procedures (adenoidectomy, uvulectomy) * pregnancy, breastfeeding * asthma, epilepsy * concurrent illness with impairment of wound-healing (diabetes, vascular disease) * allergy or contraindication to use of protocol medication (dipyrone) * inability to comply with the protocol conditions.

Keywords: tonsillectomy pain homeopathy traumeel
airway dysfunction and remodelling in athletes following swimming training in chlorinated pools

Conditions: Asthma; Airway Hyperresponsiveness

Summary: swimmers show the highest prevalence of asthma among elite athletes, certainly due to chlorine exposure. the consequences of a chronic exposure to chlorine compounds by swimmers and the mechanisms of asthme in this population are still poorly documented. specific diagnostic criteria have been proposed by the international olympic committee - medical council (ioc-mc) and world anti-doping agency (wada) to determine the presence of asthma in athletes. using the more specific bronchial provocation tests, our aims are 1. to compare the prevalence of asthma in swimmers and control subjects 2. to analyze the influence of chlorine exposure on bronchial inflammatory processes in swimmers versus control subjects 3. to study the time-course of changes in airway symptoms, responsiveness, inflammation and remodeling after cessation of training


Eligibility criteria:
inclusion criteria: * 14 to 35 years old * to swim at least 10h per week * for control subjects, non-competitive healthy subjects exclusion criteria: * any disease that may interfere with the tests for the controls * triathletes are excluded * smokers * obese or with a bmi more than 29 * former athletes (control group)

Keywords: asthma airway hyperresponsiveness swimmers airway inflammation airway remodelling
flt-pet activity change after allogeneic umbilical cord blood (ucb) therapy in cerebral palsy

Conditions: Cerebral Palsy

Summary: this is randomized placebo-controlled trial to recognize new cell regeneration in the brain using flt-pet.

flt(3'-deoxy-3'-\[f-18\]fluorothymidine) has been developed as a cell-proliferation tracer. in animal study, flt-pet was used as a tool that enables imaging and measuring of proliferation in the brain, thus it detects activity of endogenous neural stem cells noninvasively. this study aims to assess cell proliferation activity changes in the brain after umbilical cord blood (ucb)therapy for cerebral palsy patients using flt-pet.

Eligibility criteria:
inclusion criteria: * cerebral palsy * abnormal muscle tone * gross motor function classification system (gmfcs): i, ii, iii, iv, v * willing to comply with all study procedure exclusion criteria: * medical instability including pneumonia or renal function at enrollment * presence of known genetic disease * presence of drug hypersensitivity which is related to this study remedy * poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up * decision by the principal investigator when there are unexpected events including brain surgery, that may affect the outcome

Keywords: cerebral palsy umbilical cord blood flt-pet
circulating tumor cells in lung cancer

Conditions: Stage IIIB Non Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer

Summary: title : circulating tumor cells identification in advanced stage non-small cell lung cancer (circubronch) background : circulating tumor cells identification is a new field of research in oncology, and some studies have been conducted with success on breast and prostate cancer. nearly 80% of lung cancers are diagnosed in an advanced stage (iiib, and iv). circulating tumor cells identification and monitoring these cells after treatment could help the clinicians to detect relapse or be a prognostic factor. primary objective : circulating tumor cells identification, and monitoring in advanced stage lung cancers (iiib and iv). secondary objectives : predictive value of the monitoring of circulating tumor cells on the therapeutic response. prognostic value of identification of circulating tumor cells at the time of diagnosis. study design : this study is a prospective, monocentrique trial analyzing the identification of circulating tumor cells in stage iiib, and iv non-small cell lung cancers. duration of the inclusions: 54 months. duration of the study: 66 months. procedures : detection of circulating tumor cells with cellsearch system (veridex), and a cut-off of 5 cells/7,5 ml of blood. sample size : 200 patients statistical analysis : detection of circulating tumor cells is predicted in 20% of stage iiib, and iv non-small cell lung cancers included in this study. the cut-off is 5 circulating tumor cells per 7,5 ml of blood.


Eligibility criteria:
inclusion criteria: * advanced stage nsclc (stages iiib, and iv) with measurable or evaluable disease at diagnosis. * age ≥ 18 years. * measurable or evaluable disease according to recist criteria. * ability to sign informed consent. exclusion criteria: * prior cancers within 5 years, except for non-melanoma skin cancers, and in situ cervical cancers. * prior chemotherapy, radiation or surgery for lung cancer. * inability to comply with study and/or follow-up procedures.

Keywords: lung cancer circulating tumor cells prospective monocentrique trial
siello pilot study for comparison of steroid versus non-steroid pacing leads

Conditions: Arrhythmias, Cardiac

Summary: this investigation is designed to demonstrate the clinical efficacy and safety of the low-dose drug of the siello leads in comparison to the non-steroid bppu leads in a clinical investigation.


Eligibility criteria:
inclusion criteria: * meet the indications for pacemaker therapy * understand the nature of the procedure * give informed consent * able to complete all testing required by the clinical protocol * available for follow-up visits on a regular basis at the investigational site exclusion criteria: * meet none of the pacemaker indications * meet one or more of the contraindications * have a life expectancy of less than six months * cardiac surgery in the next six months * enrolled in another cardiac clinical investigation * have other medical devices that may interact with the implanted pacemaker

Keywords: steroid, leads, threshold, pacemaker
cumulative and booster effects of multisession prefrontal transcranial direct current stimulation in adolescents with asd

Conditions: Transcranial Direct Current Stimulation; Autistic Spectrum Disorder; Electroencephalography; Booster Effects

Summary: autism spectrum disorder (asd) is a pervasive and lifelong developmental disorder that currently affects 1 in 54 children. individuals with autism are often severely impaired in communication, social skills, and cognitive functions. particularly detrimental characteristics typical of asd include the inability to relate to people and the display of repetitive stereotyped behaviors and uncontrollable temper outbursts over trivial changes in the environment, which often cause emotional stress for the children, their families, schools and neighborhood communities. to date, there is no cure for asd, and the disorder remains a highly disabling condition. recently, transcranial direct current stimulation (tdcs), a noninvasive neuromodulation technique, has shown great promise as an effective and cost-effective tool for reducing core symptoms, such as anxiety, aggression, impulsivity, and poor social communication, in patients with autism. although the empirical findings in patients with asd are encouraging, it remains to be determined whether these experimental data can be translated into real-world benefits. an important next step is to better understand the factors affecting the long-term efficacy of tdcs treatment - in particular, the possible risk factors associated with relapse in patients with asd and the role of booster session tdcs as an add-on treatment to induce long-lasting neuroplastic effects in asd.


Eligibility criteria:
inclusion criteria: * individuals who are confirmed by a clinical psychologist based on the diagnostic and statistical manual of mental disorders-5th ed (dsm-v) criteria of autism spectrum disorder and structured interview with their parents or primary caregivers on their developmental history using the autism diagnostic interview-revised (adi-r). * individuals with asd who are comorbid with adhd symptoms will be included if they were willing to abstain from the use of these medications at least 96 hours before the commencement, until the completion, of the treatment. * in view of the fact that neuroadaptation to antipsychotics typically occurs within six months, potential participants who are prescribed antipsychotic medications will only be included if the dosage of the medication remained unchanged for six months or more before the experimental period. exclusion criteria: * individuals without a confirmed diagnosis from the clinical psychologist, with a history of other neurological and psychiatric disorders and head trauma, or on psychiatric medication will be excluded from the study. * in view of the possibility of seizure induction by tdcs, potential asd participants comorbid with epilepsy will be excluded. * potential participants comorbid with mood or anxiety disorders will also be excluded.

Keywords: autism asd tdcs treatment outcome eeg e/i ratio booster effects cognitive function
crux biomedical ivc filter - evaluation of the crux inferior vena cava filter system (retrieve)

Conditions: Pulmonary Embolism

Summary: this is an open label, non-randomized, prospective, multicenter study.


Eligibility criteria:
inclusion criteria: patients for this study must meet the following inclusion criteria to be eligible for enrollment: 1. the patient is \>18 years of age. 2. patient is considered a candidate for the ivcf under one of the following indications: * proven pe * recurrent pe despite adequate anticoagulation * contraindication to anticoagulation * inability to achieve/maintain therapeutic anticoagulation * iliocaval dvt * large, free-floating proximal (i.e. ileofemoral) dvt * massive pe treated with thrombolysis/thrombectomy * chronic pe treated with thrombectomy * protection during thrombolysis for iliocaval dvt * pe with limited cardiopulmonary reserve * poor compliance with anticoagulant medications * high risk of injury worsened by anticoagulation (e.g., ataxia, falls) * multi-trauma patient with high risk of pe * surgical patients at high risk of pe * medical condition with high risk of pe 3. patient has a vena cava diameter of 17-28mm. 4. the patient or legal guardian has been informed of the nature of the study and agrees to its provisions and has provided informed written consent. 5. the patient is willing to be available for the appropriate follow-up for the duration of the study. 6. the patient has suitable ivc anatomy that would allow infra-renal placement of the filter. exclusion criteria: patients who have any of the following exclusion criteria are not eligible for the study: 1. the patient has one of the following conditions: * renal vein thrombosis * ivc thrombosis extending to renal veins * duplicate ivc * gonadal vein thrombosis * requires supra-renal filter placement 2. the patient has an uncontrolled infectious disease. 3. the patient is at risk for aseptic pe. 4. patient has uncontrollable coagulopathy. 5. patient has an existing ivcf. 6. the patient has a life expectancy of less than 6 months. 7. the patient is pregnant. 8. the patient has a condition that inhibits radiographic visualization of the ivc. 9. the patient has a known allergy or intolerance to polytetrafluoroethylene (ptfe) or nitinol. 10. the patient has a known hypersensitivity to contrast which cannot be pre-treated. 11. the patient's access vessels preclude safe insertion of the delivery system. 12. the patient is participating in another device or drug study. patient must have completed the follow- up phase of any previous study at least 30 days prior to enrollment into this trial. the patient may only be enrolled in this study once. 13. the patient is unable and/or unwilling to cooperate with study procedures or required follow-up visits.
effect of heated breathing circuit on intraoperative core temperature and systemic inflammation after brain surgery: a prospective randomized study

Conditions: Patients Scheduled for Brain Surgery

Summary: mechanical respiration during general anesthesia causes cold and dry gases to reach the lower airway, reduce the function of the airway mucosa, and cause accumulation of secretions. inhaled dry gas is one of the causes of hypothermia during general anesthesia. to overcome this, the warm-humidifying breathing circuit uses warm, moisture-preserving gas to promote mucus mobility of the airway mucosal ciliate cells and prevents cold gases from evaporating from the mucosal surfaces which results lowering body temperature. we aimed to investigate the effect of newly developed sohum warm humidifying respiration circuit (sh501) on the prevention of core body temperature reduction during surgery and systemic inflammation reaction.


Eligibility criteria:
inclusion criteria: 1. age ≥ 19 2. scheduled for brain surgery exclusion criteria: 1. age \< 19 2. patients with severe obstructive lung disease and/or restrictive lung disease patients 3. patients with infectious disease 4. surgery with prone position or lateral position 5. arrhythmia
effectiveness & tolerability of novel, initial triple combination therapy vs conventional therapy in type 2 diabetes

Conditions: Diabetes Mellitus, Type II

Summary: in this study, the investigators will assess the efficacy and tolerability of a novel, initial triple combination therapy with metformin, saxaglipitin, and dapagliflozin, compared to conventional stepwise add-on therapy in drug-naïve patients with recently onset type 2 diabetes.

ada/easd guideline recommends sequential treatment approach starting with metformin, and adding other classes of anti-diabetic medications if target hba1c is not achieved. however, several clinical studies clearly showed that initial dual or triple combination therapy was more favorable in terms of glycemic control. a dpp-4 inhibitor saxagliptin increases serum level of glp-1, and potentiates its action of increasing glucose-dependent insulin secretion and lowering glucagon secretion. a sglt-2 inhibitor dapagliflozin lowers hyperglycemia via blocking sglt-2 to increase glucosuria, that is, in an insulin-independent manner. therefore, the mechanism of action of these drugs are complimentary to that of metformin, and all of these have a low risk of hypoglycemia and weight gain.

Eligibility criteria:
inclusion criteria: * drug-naïve patients with type 2 diabetes by american diabetes association criteria * hba1c ≥ 8%, \< 10.5% at screening * age ≥ 18 years, \< 65 years * body mass index (bmi) ≥ 23 kg/m2, \< 35 kg/m2 * estimated gfr (egfr) ≥ 60 ml/min/1.73m2 exclusion criteria: * uncontrolled hyperglycemia \> 270 mg/dl after an overnight fast * diabetic ketoacidosis * type 1 diabetes * confirmed cardiovascular disease (acute coronary syndrome, stroke, or transient ischemic attack) within 3 months of screening * congestive heart failure (new york heart association functional class iv) * severe hepatic dysfunction (serum levels of either ast, alt, or alkaline phosphatase above 3 x upper limit of normal (uln)) * alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake * pregnant women, women with potential of pregnancy not using adequate contraception method as evaluated by the investigator, lactating women * use of systemic glucocorticoid
effect of intravesical b.c.g and gemcitabine on semen quality and testicular volume

Conditions: Urothelial Carcinoma Bladder; Sperm Count, Low; Testis; Fibrosis

Summary: to evaluate the effects of local intravesical b.c.g and gemcitabine on semen quality and testicular volume.

local chemotherapy has become one of the alternative strategies in treatment of cancer as many side effects on organs in human body. despite this, also local chemotherapy has adverse effects too. one of these cancers in which local chemotherapy is used and one of the most five prevalent cancers in egyptian men and the 3rd highest incidence numbers for specific cancer cases in egypt in 2020,also it represents the 3rd highest mortality number from cancer in egypt by 19% of men's mortality is bladder cancer. it is divided according to the staging system into 2 main types: the non-muscle invasive (t1) and muscle invasive (t2).the most common method used to treat t1 baldder cancer are turt followed by local intravesical immunotherapy (like bacillus calmette guerin) and chemotherapy (gemcitabine and mitomycin c). these drugs systemically can cause side effects like urgency, frequency, low grade fever, malaise, effect on high proliferative tissues like bone marrow, skin, hair, and seminiferous tubules....etc. some rare side effects are acute respiratory distress syndrome and hepatic toxicity. the effect of these drugs on seminiferous tubules is still a controversy as most of the research field is focusing on systemic use, also the lack of researches focusing on local intravesical use. it can cause infertility especially in young patients with cancer who seek fertility and they are not married or not having children. the problem of fertility and urogenital cancer is multifactorial and there is a gap of knowledge as low incidence number of bladder cancer in young patients and the lack of he studies focusing on fertility in cancer patients. this study is going to unmask the mystery of one of local immunotherapy and immunotherapy and there effect on semen and testicles.

Eligibility criteria:
inclusion criteria: 1. male patients from 20 to 60's year old (the years of reproductive active men) 2. non muscle invasive bladder (t1 or less) urothelial carcinoma who are elected to intravesical immunotherapy or chemotherapy after turt exclusion criteria: i. t1 carcinomas of bladder in which intravesical immunotherapy and chemotherapy is contraindicated ii. patients under conditions that may affect sperm number, e.g. systemic chemotherapy, radiotherapy and previous history of genitourinary tuberculosis, prostatic carcinoma,...etc iii. abnormal semen parameters or abnormal hormonal profile (hypogonadism) that interfere with the study, especially azoospermia and aspermia
lol: it's all improv after cancer!™

Conditions: Breast Cancer; Psychological Distress

Summary: this is a 2-arm randomized waitlist controlled trial. a total of 46 of subjects are planned. subjects will be assigned to the intervention vs. waitlist control group in a randomized fashion. all subjects will complete baseline assessments prior to randomization. baseline assessments will be completed within two weeks before the start of the improv series. subjects in the intervention group will complete 6 consecutive improv classes. patients in the control group will be permitted to complete the improv course (within 10-12 weeks) and follow-up after their 10 week control timeline is complete. evaluations for the intervention group will be taken at baseline (t0), the last day of class (t1), one month after the last day of class (t2), and 6 months after the last day of class (t3). evaluations for the waitlist control group will be taken at baseline #1 (t0), 6 weeks after t0 (t1), one month after t1 (t2), first day of class (baseline 2, t0b), last day of class (t1b), one month after the last day of class (t2b), and 6 months after the last day of class (t3b). screening data will be reviewed to determine subject eligibility. subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. total duration of the study is expected to be 2 years.


Eligibility criteria:
inclusion criteria: * diagnosed with breast cancer stage 1-3 (no distant metastases) * completed cancer treatment (including chemotherapy, radiation therapy, biologic treatment, and/or any combination). at time of consent, patient must be at least 2 months (60 days) from their last treatment and no more than 18 months (547 days) post-treatment. long term hormonal/biologic treatments are ok. * adult female age ≥18 * scores ≤82 on the fact-g (patients do not need to maintain score ≤82 after initial screening fact-g to remain on study) * agrees to complete study surveys * agrees to attend at least 4 of 6 improv classes * english speaking * reasonable medical stability (per physician clearance). * emotionally stable (per physician clearance) to participate in this series. * written informed consent obtained from subject and ability for subject to comply with the requirements of the study. exclusion criteria: * patients who have significant personality disorders or unstable psychiatric disorders that are severe enough to detract from the group process, as determined by their treating physician. * patients with severe cognitive impairments, as determined by their treating physician. * non-english speakers. * patients who have previously participated in an improvisational comedy program in the past year.